IMMX
Immix Biopharma, Inc.
Biotechnology
Market Cap$441M
5Y Perf.+137.4%
Build Your Comparison
Side-by-side financial analysisIMMX
PRAX
ACAD
BEAM
Try popular comparisons:
Stock Comparison
IMMX vs PRAX vs ACAD vs BEAM
Revenue, margins, valuation, and 5-year total return — side by side.
PRAX
Praxis Precision Medicines, Inc.
Biotechnology
Market Cap$7.16B
5Y Perf.-9.8%
ACAD
ACADIA Pharmaceuticals Inc.
Biotechnology
Market Cap$3.66B
5Y Perf.-9.6%
BEAM
Beam Therapeutics Inc.
Biotechnology
Market Cap$3.02B
5Y Perf.-63.6%
IMMX vs PRAX vs ACAD vs BEAM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  IMMX |  PRAX |  ACAD |  BEAM |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $441M | $7.16B | $3.66B | $3.02B |
| Revenue (TTM) | $0.00 | $0.00 | $1.10B | $132M |
| Net Income (TTM) | $-35M | $-327M | $376M | $-65M |
| Gross Margin | — | — | 91.5% | -64.2% |
| Operating Margin | — | — | 7.4% | -281.0% |
| Forward P/E | — | — | 54.2x | — |
| Total Debt | $1M | $110K | $52M | $294M |
| Cash & Equiv. | $94M | $357M | $178M | $295M |
IMMX vs PRAX vs ACAD vs BEAM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
IMMX
PRAX
ACAD
BEAM
| Stock | Dec 21 | Jun 26 | Return |
|---|---|---|---|
| Immix Biopharma, In… (IMMX) | 100 | 237.4 | +137.4% |
| Praxis Precision Me… (PRAX) | 100 | 90.2 | -9.8% |
| ACADIA Pharmaceutic… (ACAD) | 100 | 90.4 | -9.6% |
| Beam Therapeutics I… (BEAM) | 100 | 36.4 | -63.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IMMX vs PRAX vs ACAD vs BEAM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ACAD leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Praxis Precision Medicines, Inc. is the stronger pick specifically for recent price momentum and sentiment. BEAM also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
🥇ACAD emerged as the overall leader. Track its performance:
IMMX
Immix Biopharma, Inc.
The Long-Run Compounder
IMMX is the clearest fit if your priority is long-term compounding.
- 120.7% 10Y total return vs PRAX's -40.5%
Best for: long-term compounding
PRAX
Praxis Precision Medicines, Inc.
The Defensive Pick
PRAX is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.
- Lower volatility, beta 1.55, Low D/E 0.0%, current ratio 10.22x
- Beta 1.55, current ratio 10.22x
- +456.0% vs ACAD's -4.1%
Best for: sleep-well-at-night and defensive
ACAD
ACADIA Pharmaceuticals Inc.
The Income Pick
ACAD carries the broadest edge in this set and is the clearest fit for income & stability.
- beta 1.12
- 34.3% margin vs BEAM's -49.2%
- Beta 1.12 vs BEAM's 2.27, lower leverage
- 26.2% ROA vs IMMX's -59.2%, ROIC 10.0% vs -21.7%
Best for: income & stability
BEAM
Beam Therapeutics Inc.
The Growth Play
BEAM is the clearest fit if your priority is growth exposure.
- Rev growth 120.0%, EPS growth 82.3%, 3Y rev CAGR 31.9%
- 120.0% revenue growth vs PRAX's -100.0%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  BEAM | 120.0% revenue growth vs PRAX's -100.0% |
| Quality / Margins |  ACAD | 34.3% margin vs BEAM's -49.2% |
| Stability / Safety | ACAD | Beta 1.12 vs BEAM's 2.27, lower leverage |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) |  PRAX | +456.0% vs ACAD's -4.1% |
| Efficiency (ROA) | ACAD | 26.2% ROA vs IMMX's -59.2%, ROIC 10.0% vs -21.7% |
IMMX vs PRAX vs ACAD vs BEAM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
FY 2018
Segment breakdown not available.
IMMX vs PRAX vs ACAD vs BEAM — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLACADLAGGINGPRAX
Who Leads Where
ACAD leads in 2 of 6 categories
BEAM leads 1 • IMMX leads 0 • PRAX leads 0 • 2 tied
Explore the data ↓PRAXPraxis Precision Medi…
0leads
IMMXImmix Biopharma, Inc.
0leads
BEAMBeam Therapeutics Inc.
1leads
ACADACADIA Pharmaceutical…
2leads
6 Total Categories
CATEGORYLEADERvs BEAMvs IMMXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ACAD5/6
Valuation MetricsMultiples, price ratios, and targets
BEAM2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ACAD5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ACAD leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ACAD and PRAX operate at a comparable scale, with $1.1B and $0 in trailing revenue. ACAD is the more profitable business, keeping 34.3% of every revenue dollar as net income compared to BEAM's -49.2%. On growth, ACAD holds the edge at +9.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric |  IMMXImmix Biopharma, … | PRAXPraxis Precision … | ACADACADIA Pharmaceut… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $0 | $1.1B | $132M |
| EBITDAEarnings before interest/tax | -$36M | -$357M | $96M | -$355M |
| Net IncomeAfter-tax profit | -$35M | -$327M | $376M | -$65M |
| Free Cash FlowCash after capex | -$33M | -$283M | $212M | -$384M |
| Gross MarginGross profit ÷ Revenue | — | — | +91.5% | -64.2% |
| Operating MarginEBIT ÷ Revenue | — | — | +7.4% | -2.8% |
| Net MarginNet income ÷ Revenue | — | — | +34.3% | -49.2% |
| FCF MarginFCF ÷ Revenue | — | — | +19.4% | -2.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | +9.7% | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -20.0% | +2.7% | -81.8% | +26.6% |
ACAD leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
BEAM leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | IMMXImmix Biopharma, … | PRAXPraxis Precision … | ACADACADIA Pharmaceut… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| Market CapShares × price | $441M | $7.2B | $3.7B | $3.0B |
| Enterprise ValueMkt cap + debt − cash | $348M | $6.8B | $3.5B | $3.0B |
| Trailing P/EPrice ÷ TTM EPS | -9.10x | -18.40x | 9.34x | -36.31x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 54.20x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 25.46x | — |
| Price / SalesMarket cap ÷ Revenue | — | — | 3.42x | 21.62x |
| Price / BookPrice ÷ Book value/share | 2.85x | 6.36x | 2.99x | 2.35x |
| Price / FCFMarket cap ÷ FCF | — | — | 34.83x | — |
BEAM leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
ACAD leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
ACAD delivers a 35.6% return on equity — every $100 of shareholder capital generates $36 in annual profit, vs $-73 for IMMX. PRAX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to BEAM's 0.24x. On the Piotroski fundamental quality scale (0–9), ACAD scores 6/9 vs PRAX's 3/9, reflecting solid financial health.
| Metric | IMMXImmix Biopharma, … | PRAXPraxis Precision … | ACADACADIA Pharmaceut… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -73.2% | -43.0% | +35.6% | -5.9% |
| ROA (TTM)Return on assets | -59.2% | -40.2% | +26.2% | -4.6% |
| ROICReturn on invested capital | -21.7% | -65.0% | +10.0% | -31.1% |
| ROCEReturn on capital employed | -49.9% | -49.3% | +10.1% | -33.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 | 6 | 4 |
| Debt / EquityFinancial leverage | 0.01x | 0.00x | 0.04x | 0.24x |
| Net DebtTotal debt minus cash | -$93M | -$357M | -$126M | -$1M |
| Cash & Equiv.Liquid assets | $94M | $357M | $178M | $295M |
| Total DebtShort + long-term debt | $1M | $110,000 | $52M | $294M |
| Interest CoverageEBIT ÷ Interest expense | — | — | — | 1.08x |
ACAD leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — IMMX and PRAX each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMMX five years ago would be worth $22,071 today (with dividends reinvested), compared to $3,313 for BEAM. Over the past 12 months, PRAX leads with a +456.0% total return vs ACAD's -4.1%. The 3-year compound annual growth rate (CAGR) favors PRAX at 158.5% vs ACAD's -4.6% — a key indicator of consistent wealth creation.
| Metric | IMMXImmix Biopharma, … | PRAXPraxis Precision … | ACADACADIA Pharmaceut… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +49.2% | -13.4% | -18.2% | +8.4% |
| 1-Year ReturnPast 12 months | +233.3% | +456.0% | -4.1% | +64.4% |
| 3-Year ReturnCumulative with dividends | +303.0% | +1628.1% | -13.1% | -10.8% |
| 5-Year ReturnCumulative with dividends | +120.7% | -17.6% | -22.0% | -66.9% |
| 10-Year ReturnCumulative with dividends | +120.7% | -40.5% | -43.9% | +56.9% |
| CAGR (3Y)Annualised 3-year return | +59.1% | +158.5% | -4.6% | -3.7% |
Evenly matched — IMMX and PRAX each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ACAD and BEAM each lead in 1 of 2 comparable metrics.
Risk & Volatility
ACAD is the less volatile stock with a 1.12 beta — it tends to amplify market swings less than BEAM's 2.27 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BEAM currently trades 80.7% from its 52-week high vs PRAX's 67.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | IMMXImmix Biopharma, … | PRAXPraxis Precision … | ACADACADIA Pharmaceut… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.72x | 1.55x | 1.10x | 2.18x |
| 52-Week HighHighest price in past year | $11.61 | $366.52 | $27.81 | $36.44 |
| 52-Week LowLowest price in past year | $1.94 | $37.19 | $19.69 | $15.60 |
| % of 52W HighCurrent price vs 52-week peak | +69.8% | +67.7% | +76.9% | +80.7% |
| RSI (14)Momentum oscillator 0–100 | 40.6 | 28.6 | 46.3 | 48.7 |
| Avg Volume (50D)Average daily shares traded | 941K | 394K | 1.5M | 1.9M |
Evenly matched — ACAD and BEAM each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: IMMX as "Buy", PRAX as "Buy", ACAD as "Buy", BEAM as "Buy". Consensus price targets imply 144.8% upside for PRAX (target: $607) vs 62.6% for ACAD (target: $35).
| Metric | IMMXImmix Biopharma, … | PRAXPraxis Precision … | ACADACADIA Pharmaceut… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $17.00 | $607.15 | $34.78 | $48.00 |
| # AnalystsCovering analysts | 4 | 16 | 37 | 27 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | 0 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ACAD leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). BEAM leads in 1 (Valuation Metrics). 2 tied.
Best OverallACADIA Pharmaceuticals Inc. (ACAD)Leads 2 of 6 categories
Loading custom metrics...
IMMX vs PRAX vs ACAD vs BEAM: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is IMMX or PRAX or ACAD or BEAM a better buy right now?
For growth investors, Beam Therapeutics Inc.
(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 3x trailing P/E (54. 2x forward), making it the more compelling value choice. Analysts rate Immix Biopharma, Inc. (IMMX) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — IMMX or PRAX or ACAD or BEAM?
Over the past 5 years, Immix Biopharma, Inc.
(IMMX) delivered a total return of +120. 7%, compared to -66. 9% for Beam Therapeutics Inc. (BEAM). Over 10 years, the gap is even starker: IMMX returned +130. 2% versus ACAD's -44. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — IMMX or PRAX or ACAD or BEAM?
By beta (market sensitivity over 5 years), ACADIA Pharmaceuticals Inc.
(ACAD) is the lower-risk stock at 1. 10β versus Beam Therapeutics Inc. 's 2. 18β — meaning BEAM is approximately 98% more volatile than ACAD relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 24% for Beam Therapeutics Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — IMMX or PRAX or ACAD or BEAM?
By revenue growth (latest reported year), Beam Therapeutics Inc.
(BEAM) is pulling ahead at 120. 0% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Beam Therapeutics Inc. grew EPS 82. 3% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Over a 3-year CAGR, BEAM leads at 31. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — IMMX or PRAX or ACAD or BEAM?
ACADIA Pharmaceuticals Inc.
(ACAD) is the more profitable company, earning 36. 5% net margin versus -57. 2% for Beam Therapeutics Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus -274. 6% for BEAM. At the gross margin level — before operating expenses — ACAD leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is IMMX or PRAX or ACAD or BEAM more undervalued right now?
Analyst consensus price targets imply the most upside for PRAX: 144.
8% to $607. 15.
07Which pays a better dividend — IMMX or PRAX or ACAD or BEAM?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is IMMX or PRAX or ACAD or BEAM better for a retirement portfolio?
For long-horizon retirement investors, ACADIA Pharmaceuticals Inc.
(ACAD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 10)). Beam Therapeutics Inc. (BEAM) carries a higher beta of 2. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACAD: -44. 6%, BEAM: +54. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between IMMX and PRAX and ACAD and BEAM?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: IMMX is a small-cap quality compounder stock; PRAX is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock; BEAM is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.